Project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases

Acronym NeuroMET2 (Reference Number: 18HLT09)
Duration 01/07/2019 - 30/06/2022
Project Topic Neurodegenerative diseases (NDDs) are a major health challenge for society; over 9.9 million new cases of dementia are identified worldwide each year, while annual care costs in Europe currently run to €130 billion. More accurate and earlier diagnosis would enable more effective treatment and improve forecasting of disease progression. Improved evaluation of NDD therapies is also needed before clinical uptake can occur. This project aims to develop the most promising, minimally invasive, measurement methods for early NDD diagnosis and will support development of targeted (patient-specific) therapies. The project will lead to improvements in the resolution of magnetic resonance imaging (MRI) and other scanning technologies, validate biomarker measurements and develop a smartphone based cognitive test app – all designed for eventual clinical use. Measurement protocols will support standardisation for early NDD diagnosis and new therapies, enabling development of screening programmes for improved quality of life.
Website visit project website
Network EMPIR
Call EMPIR Call 2018

Project partner

Number Name Role Country
1 LGC Limited Coordinator United Kingdom
2 Laboratoire national de métrologie et d'essais Partner France
3 Physikalisch-Technische Bundesanstalt Partner Germany
4 RISE Research Institutes of Sweden AB Partner Sweden
5 Charite - Universitaetsmedizin Berlin Partner Germany
6 Centre Hospitalier Universitaire Montpellier Partner France
7 Modus Outcomes SAS Partner France
8 Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts Partner Germany
9 Stichting VUmc Partner Netherlands
10 Högskolan Kristianstad Observer Sweden